Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptors, progesterone receptors, and HER2 amplification. Because it does not express these common targets, TNBC does not respond to standard hormone therapies or HER2 targeted drugs, making treatment more challenging and prognosis generally poorer.

Research shows TNBC tends to grow and spread faster than other breast cancers and is more likely to recur, especially within the first few years after treatment. It is more common in younger women, Black women, and individuals with BRCA1 mutations. Genetic and molecular studies reveal that TNBC is highly heterogeneous, with several distinct subtypes that differ in gene expression, immune activity, and potential vulnerabilities.

Standard treatment still relies heavily on surgery, chemotherapy, and radiation. However, newer therapies are changing the outlook. Immune checkpoint inhibitors that stimulate the immune system, such as PD 1 and PD L1 inhibitors, have improved outcomes for some patients, particularly when combined with chemotherapy. Antibody drug conjugates that deliver chemotherapy directly to cancer cells are also showing substantial benefit in advanced disease.

Ongoing research aims to refine molecular classifications of TNBC, identify predictive biomarkers, and develop targeted therapies against DNA repair defects, cell cycle regulators, and signaling pathways. Trials are exploring combinations of immunotherapy, PARP inhibitors, and other novel agents to overcome resistance. Overall, while TNBC remains a high risk cancer, advances in understanding its biology are leading to more personalized treatments and better survival for a growing subset of patients.